| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Cell Biology and Histology and
Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Glatiramer acetate (GA; copolymer-1, Copaxone) suppresses the induction of experimental autoimmune encephalomyelitis and reduces the relapse frequency in relapsing-remitting multiple sclerosis. Although it has become clear that GA induces protective degenerate Th2/IL-10 responses, its precise mode of action remains elusive. Because the cytokine profile of Th cells is often regulated by dendritic cells (DC), we studied the modulatory effects of GA on the T cell regulatory function of human DC. This study shows the novel selective inhibitory effect of GA on the production of DC-derived inflammatory mediators without affecting DC maturation or DC immunostimulatory potential. DC exposed to GA have an impaired capacity to secrete the major Th1 polarizing factor IL-12p70 in response to LPS and CD40 ligand triggering. DC exposed to GA induce effector IL-4-secreting Th2 cells and enhanced levels of the anti-inflammatory cytokine IL-10. The anti-inflammatory effect of GA is mediated via DC as GA does not affect the polarization patterns of naive Th cells activated in an APC-free system. Together, these results reveal that APC are essential for the GA-mediated shift in the Th cell profiles and indicate that DC are a prime target for the immunomodulatory effects of GA.
This article has been cited by other articles:
|
|
 |
|
  E. Jasny, M. Eisenblatter, K. Matz-Rensing, K. Tenner-Racz, M. Tenbusch, A. Schrod, C. Stahl-Hennig, V. Moos, T. Schneider, P. Racz, et al. IL-12-Impaired and IL-12-Secreting Dendritic Cells Produce IL-23 upon CD154 Restimulation J. Immunol., May 15, 2008; 180(10): 6629 - 6639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. H. Stern, D. B. Keskin, H. Zhang, H. Lv, Z. Kato, and J. L. Strominger Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice PNAS, April 1, 2008; 105(13): 5172 - 5176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.M. Valenzuela, K. Costello, M. Chen, A. Said, K.P. Johnson, and S. Dhib-Jalbut Clinical response to glatiramer acetate correlates with modulation of IFN-{gamma} and IL-4 expression in multiple sclerosis Multiple Sclerosis, July 1, 2007; 13(6): 754 - 762. [Abstract] [PDF]
|
|
|
|
|
|
E. Piaggio, L. T. Mars, C. Cassan, J. Cabarrocas, M. Hofstatter, S. Desbois, E. Bergereau, O. Rotzschke, K. Falk, and R. S. Liblau Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance PNAS, May 29, 2007; 104(22): 9393 - 9398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Horani, N. Muhanna, O. Pappo, A. Melhem, C. E. Alvarez, S. Doron, W. Wehbi, K. Dimitrios, S. L. Friedman, and R. Safadi Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G628 - G638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Tennakoon, R. S. Mehta, S. B. Ortega, V. Bhoj, M. K. Racke, and N. J. Karandikar Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis. J. Immunol., June 1, 2006; 176(11): 7119 - 7129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Allie, L. Hu, K. M. Mullen, S. Dhib-Jalbut, and P. A. Calabresi Bystander Modulation of Chemokine Receptor Expression on Peripheral Blood T Lymphocytes Mediated by Glatiramer Therapy Arch Neurol, June 1, 2005; 62(6): 889 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. K. Singh and J. Z. Zhang Differential Activation of ERK, p38, and JNK Required for Th1 and Th2 Deviation in Myelin-Reactive T Cells Induced by Altered Peptide Ligand J. Immunol., December 15, 2004; 173(12): 7299 - 7307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Arnon and R. Aharoni Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications PNAS, October 5, 2004; 101(suppl_2): 14593 - 14598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hohlfeld and H. Wekerle Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines PNAS, October 5, 2004; 101(suppl_2): 14599 - 14606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Weber, M. Starck, S. Wagenpfeil, E. Meinl, R. Hohlfeld, and C. Farina Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo Brain, June 1, 2004; 127(6): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Kim, I. Ifergan, J. P. Antel, R. Seguin, M. Duddy, Y. Lapierre, F. Jalili, and A. Bar-Or Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis J. Immunol., June 1, 2004; 172(11): 7144 - 7153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weir, C. C. A. Bernard, and B. T. Backstrom IL-5-deficient mice are susceptible to experimental autoimmune encephalomyelitis Int. Immunol., November 1, 2003; 15(11): 1283 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Bradl and R Hohlfeld Molecular pathogenesis of neuroinflammation J. Neurol. Neurosurg. Psychiatry, October 1, 2003; 74(10): 1364 - 1370. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
